Your browser doesn't support javascript.
loading
Continuous renal replacement therapy with vitamin E-coated polysulfone hemofilter reduces inflammatory responses in a porcine lipopolysaccharide-treated model.
Horikawa, Takumi; Yagi, Kana; Ishikawa, Chika; Atarashi, Machi; Watanabe, Atsushi; Kato, Yoshihisa.
Affiliation
  • Horikawa T; Medical Technology and Material Laboratory, Research and Business Development Division, Asahi Kasei Medical Co., LTD., Shizuoka, Japan.
  • Yagi K; Medical Technology and Material Laboratory, Research and Business Development Division, Asahi Kasei Medical Co., LTD., Shizuoka, Japan.
  • Ishikawa C; Medical Technology and Material Laboratory, Research and Business Development Division, Asahi Kasei Medical Co., LTD., Shizuoka, Japan.
  • Atarashi M; Medical Technology and Material Laboratory, Research and Business Development Division, Asahi Kasei Medical Co., LTD., Shizuoka, Japan.
  • Watanabe A; Medical Technology and Material Laboratory, Research and Business Development Division, Asahi Kasei Medical Co., LTD., Shizuoka, Japan.
  • Kato Y; Medical Technology and Material Laboratory, Research and Business Development Division, Asahi Kasei Medical Co., LTD., Shizuoka, Japan.
Ther Apher Dial ; 2024 Jul 03.
Article in En | MEDLINE | ID: mdl-38960621
ABSTRACT

INTRODUCTION:

Biological invasions may promote the onset of systemic inflammatory response syndrome in patients eligible for continuous renal replacement therapy (CRRT), leading to poor prognosis. Hence, we aimed to examine the inflammatory reactions in circulation using vitamin E-coated polysulfone hollow fiber membrane (ViLIFE).

METHODS:

Lipopolysaccharides were intravenously administered to pigs (2 µg/kg/30 min) to establish an acute inflammation model. Extracorporeal circulation was performed for 6 h in continuous venovenous hemodiafiltration mode using a hemofilter for CRRT filled with a polysulfone hollow fiber membrane or ViLIFE, and the differences in inflammatory reactions were evaluated.

RESULTS:

The ViLIFE group exhibited low platelet and cytokine levels (p < 0.05 vs. sham-CRRT group). Additionally, the ViLIFE group had lower lactate and high mobility group box 1 levels than the other groups.

CONCLUSION:

ViLIFE represents a promising CRRT modality that can inhibit the inflammatory response in circulation and inhibit further biological invasions.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Ther Apher Dial Journal subject: HEMATOLOGIA Year: 2024 Document type: Article Affiliation country: Japón

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Ther Apher Dial Journal subject: HEMATOLOGIA Year: 2024 Document type: Article Affiliation country: Japón